Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Fodelia Oyj: Share Repurchase 9.1.2024

Fodelia Oyj Announcement  9.1.2024 Fodelia Oyj: Share Repurchase 9.1.2024 In the Helsinki Stock Exchange Trade date           9.1.2024Bourse trade         BuyShare                  FODELIAAmount             2 200 SharesAverage price/ share    5,7200 EURTotal cost            12 584,00 EUR Fodelia Oyj now holds a total of 24 273 sharesincluding the shares repurchased on 9.1.2024 On behalf of Fodelia Oyj Nordea Bank Oyj Janne Sarvikivi

Extension of Zero Coupon Bond

9 January 2024   Quantum Blockchain Technologies Plc( “QBT” or “the Company”)     €3.5m Zero-Coupon Bond - Maturity Extension and amendment of YTM   Quantum Blockchain Technologies (AIM: QBT) announces that the Company has agreed with MC Strategy S.A. (an Eufingest S.A. demerged Company), the sole Bondholder of the Company’s €3.5m Zero-Coupon Bond (“Bond”) issued in 2020 (as initially announced on 9 November 2020) and then partially converted into QBT new ordinary shares for €1m on 7 July 2023, to extend the maturity of the Bond from 15 December 2024 to 15 December

Immunotherapy - a new approach to treating bacterial infections, including antibiotic resistant strains

Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along with an extensive project and patent portfolio, is delighted to announce progress for the treatment of antibiotic resistant bacteria in a murine model relevant to human disease. A recent paper, clearly shows that treatment with the drug anakinra (IL-1RA) prevents severe infections of the urinary tract, including kidney infections that may cause sepsis. The treatment was efficient also against infections caused by antibiotic resistant bacteria,

Aixia Secures 10 Million SEK Contract with NexGen Cloud for Supercloud Data Center Installation in Norway

Mölndal                                                                                      2024-01-09 Aixia are happy to announce a agreement with NexGen Cloud, an international Infrastructure-as-a-Service (IaaS) giant, for the installation of a data center in Norway. The contract is valued at 10 million SEK, and the project, scheduled to take place during H1 2024 underscores Aixia's prowess in delivering advanced AI solutions and solidifies its strategic partnership with NexGen Cloud.  NexGen Cloud, an Elite member of the NVIDIA Partner Network, is set to invest a staggering $1

BioStock: CLS receives order from ClearPoint Neuro

Clinical Laserthermia Systems has received an order for ClearPoint Prism Neuro Laser Therapy System products worth 8.1 MSEK. The order comes from the American company ClearPoint Neuro, which is currently conducting a limited market release in North America ahead of the full market launch planned for the second half of 2024.Read the full article at biostock.se : https://www.biostock.se/en/2024/01/cls-receives-order-from-clearpoint-neuro/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

GomSpace signs contract with DLR for 4.7 MSEK

GomSpace and the German Aerospace Center (DLR) signs contract to initiate development of a 16U cubesat at a contract value of 4.7 MSEK.   GomSpace has today signed a contract with the German Aerospace Center (DLR). The contract covers the first phase of a project to develop a 16U cubesat. The contract value is 4,7 MSEK and the work will be carried out during first half of 2024. “GomSpace has developed solutions and missions with DLR before, recently with a successful demonstration of an optical communication payload onboard a Cubesat. It is a testament to GomSpace ability and quality,

Qt Group Joins Software-Defined Vehicle Landscape on AWS

Qt’s HMI Development Platform will be one of the first publicly available for software-defined vehicle development in AWS Marketplace; Demoed at CES 2024, featured alongside strategic Qt Group partnersLas Vegas, Nevada, 9 January 2024 - Qt Group  announced today it is joining the Software-Defined Vehicle landscape on Amazon Web Services (AWS) , making it one of the only Human-Machine Interface (HMI) development platforms available in AWS Marketplace. In doing so, Qt is widening access to its design and

Bioretec Ltd – Managers’ transactions

Bioretec Ltd      Managers’ transactions 9 January 2024 at 17.00 p.m. EETBioretec Oy - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Michael Piccirillo Position: Member of the Board/Deputy member  Issuer: Bioretec Oy LEI: 7437008736AG7HY51K13 Notification type: INITIAL NOTIFICATION Reference number: 48928/4/4 ____________________________________________ Transaction date: 2023-01-12 Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME) Instrument type: SHARE ISIN: FI4000480454

Communiqué from extraordinary general meeting of Smoltek Nanotech Holding AB (publ)

This press release is an English version of the previously published Swedish version, which has interpretive precedence. Smoltek Nanotech Holding AB (publ) held today, January 9, 2024, an extraordinary general meeting in the premises of MAQS Advokatbyrå at Östra Hamngatan 24 in Gothenburg. The chairman at the meeting was Fredrik Brusberg, associate lawyer at MAQS Advokatbyrå.The following main decisions were made at the general meeting: Approval of the board's decision on the directed issue of shares and warrants The meeting decided to, in accordance with the board's proposal, approve

Aker Horizons appoints Kristoffer Dahlberg as Chief Financial Officer

Aker Horizons ASA (OSE: "AKH") announces the appointment of Kristoffer Dahlberg as its Chief Financial Officer (CFO) with effect from 1 February 2024. Dahlberg will replace Nanna Tollefsen, who is stepping down due to family health matters. Tollefsen will continue as an executive in the Company.Dahlberg is currently the CFO of Aker Horizons Asset Development and has extensive experience throughout the Aker group, including as CFO of Aker Clean Hydrogen and VP Business Controlling at Aker BP. Prior to joining the Aker group, Dahlberg worked in management consulting and equity research. He

Save the date: Kamux organizes a Capital Markets Day on March 20, 2024

Kamux Corporation, Press Release, 9.1.2024 at 16:00 Save the date: Kamux organizes a Capital Markets Day on March 20, 2024 Kamux will organize a Capital Markets Day for investors, analysts, other representatives of the capital markets and media on March 20, 2024. The event will be held in English in Vantaa, Finland, and it will be possible to follow the event via a live webcast. At the event, Kamux’s CEO Tapio Pajuharju and other members of the Group Management Team will present the company’s updated strategy and financial targets for 2024–2026. An invitation with a detailed

OssDsign reports exceptional data from the clinical study TOP FUSION

Uppsala, January 9, 2024. OssDsign AB (publ.) today announces that positive data from the clinical study TOP FUSION has been submitted to a peer-reviewed scientific journal. Top-line results show a 93 % spinal fusion rate at 12 months as assessed with CT by independent radiological review from Medical Metrics Inc. after surgery with the novel nanosynthetic bone graft OssDsign Catalyst.The data indicates that the use of OssDsign Catalyst leads to consistent and rapid bone healing and remodeling, with improved patient outcomes as a result. They also confirm the previously reported best-in-

Elicera Therapeutics participates in a collaborative project for the development of improved CAR T-cell production that has been awarded research support of SEK 850 thousand

Gothenburg, January 9, 2024 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology platform iTANK, today announced that a collaborative project with Vecura at Karolinska University Hospital and Uppsala University has been awarded SEK 850,000 from the Center for Advanced Medical Products (CAMP). The purpose of the project is to develop an automated production process of CAR T-cells (ELC-401) for use in clinical studies.CAR T-cell therapies are produced by extracting T-cells

Fiskars Group recognizes negative goodwill from the Georg Jensen acquisition and records a gain of EUR 25.4 million as items affecting comparability – no impact on guidance for 2023

Fiskars CorporationStock exchange releaseJanuary 9, 2024 at 3.40 p.m. Fiskars Group recognizes negative goodwill from the Georg Jensen acquisition and records a gain of EUR 25.4 million as items affecting comparability – no impact on guidance for 2023 Fiskars Group has finalized[1] the purchase price allocation of the Georg Jensen acquisition and recognizes negative goodwill from it. As a result, the company records a gain of EUR 25.4 million as items affecting comparability (IAC) in Q4 2023. As the negative goodwill will be recorded as IAC in other operating income, it will not

COSEL announces launch of wide range of low profile, high efficiency power supplies for medical applications

· Highly reliable design · Certified for medical 2MOPP · Industrial OVC III · 4kV isolation · Low-profile – 30 mm · Economical design · Complies with SEMI F47 COSEL Co , Ltd (6905: Tokyo) today announced the launch of a wide range of low profile power supplies for medical applications. The WMA series  includes two families, the WMA-F and the WMA-H. The WMA-F has a universal input range of 85 to 264VAC and is available in three power levels, 35, 75 and 100W. Designed for medical systems integration

Notification of transaction by person discharging managerial responsibilities in Penneo A/S

Company Announcement No. 1-2024Copenhagen, 9 January 2024In accordance with the Market Abuse Regulation, Penneo must notify Finanstilsynet and publicly disclose transactions made by persons discharging managerial responsibilities and persons closely associated with them on trading of Penneo shares.  Penneo hereby notify and submit the attached transaction of shares in Penneo.

Orkla ASA – Increased amount in Commercial Paper (ISIN NO0013116343)

Orkla ASA has increased the amount in the above-mentioned commercial paper byNOK 500,000,000. The outstanding amount in the market after this is NOK 1,000,000,000.Start date:                  11 January 2024 Maturity:                     29 January 2024 Organised by:             Handelsbanken Capital Markets       Orkla ASA Oslo, 9 January 2024 Ref.: Senior Vice President Group Treasury Geir Solli Tlf.: +47 995 42 789

COSEL announces launch of wide range of low profile, high efficiency power supplies for medical applications

· Highly reliable design · Certified for medical 2MOPP · Industrial OVC III · 4kV isolation · Low-profile – 30 mm · Economical design · Complies with SEMI F47 COSEL Co , Ltd (6905: Tokyo) today announced the launch of a wide range of low profile power supplies for medical applications. The WMA series  includes two families, the WMA-F and the WMA-H. The WMA-F has a universal input range of 85 to 264VAC and is available in three power levels, 35, 75 and 100W. Designed for medical systems integration

Breakthrough data for first vaccine against Staphylococcal-induced Toxic Shock Syndrome (TSS) published in eClinicalMedicine, part of The Lancet Discovery Science

· Phase 2 studies showed the TSS1-T vaccine to be safe and effective, offering potential preventative therapy for vulnerable groups and medical workers · Staphylococcal-induced TSS is a serious and life-threatening condition affecting patients with compromised immunity and premenopausal women · Results encouraging for the development of a toxoid-based, multi-component vaccine against sensitive and resistant Staphylococcus aureus infections, a significant threat to patients and financial burden for healthcare systems   Vienna, Austria, 9 January 2024 – The first vaccine to

Eevia Health Plc received a multiple sales order for extract products with combined value of 347 KSEK / 31 KEUR

Eevia Health Plc’s (”Eevia” or ”The Company”) has received a series of smaller orders worth a total of 31 KEUR sales order from Slovenian and Taiwanese customers for organically certified bilberry and chaga extracts.The customers are existing customers located in Slovenia and Taiwan, who order regularly. The products are Eevia’s branded ingredient Feno-Myrtillus® 25 Organic, Feno-Myrtillus® 5 Organic, Fenoprolic® Full Spectrum (a pine bark extract) and a Chaga powder. The sales value to Eevia of the new orders is kEUR 31 and the products ordered are in stock. The order is expected to be

Olvi plc appoints Esa Hyttinen as Group General Counsel and member of Olvi Group’s Management Team

Olvi plc           Stock exchange release 9 January 2024 at 2:30 pm     Changes board/management/auditors   Olvi plc appoints Esa Hyttinen as Group General Counsel and member of Olvi Group’s Management Team Esa Hyttinen, LL.M, has been appointed as Olvi plc’s Group General Counsel and member of Olvi Group’s Management Team as of 29 February 2024. The Group General Counsel has overall responsibility for the group’s legal affairs and acts as secretary to the Board of Directors of the parent company. The position is new in the company, and Esa Hyttinen will report to Olvi CEO

Harri Salomaa appointed as Acting Managing Director of Tietoevry Create

Tietoevry Corporation     STOCK EXCHANGE RELEASE     9 January 2024 2:30 p.m. EET   Tietoevry Create, the digital engineering arm of Tietoevry, provides business advisory and design, data engineering and specialized software R&D services globally across a range of industry sectors. The business employs nearly 10 000 professionals worldwide.   After altogether nine years in the company, Christian Pedersen, Managing Director of Tietoevry Create since the business started operations in 2022, has decided to pursue interests outside of Tietoevry.   Following this, Harri Salomaa

Nordhealth Finland receives ISO/IEC 27001:2022 certification, applying highest standards of security to customer data

Helsinki, 9th January 2024: Nordhealth , the Helsinki-based healthcare software company supporting over 55,000 healthcare professionals worldwide, has announced that it has officially received ISO/IEC 27001 certification in Finland, the international standard for information security and privacy. The certification underscores Nordhealth’s dedication to safeguarding the sensitive data that it handles every day on behalf of its software users, including privately identifiable information and medical records of countless pet-owner clients and their pets.

There are no items matching the current filter
There are no more items matching the current filter
Back to top